| Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae VH Tam, PR Merlau, CS Hudson, EG Kline, BM Eales, J Smith, AK Sofjan, ... Journal of Antimicrobial Chemotherapy 77 (11), 3130-3137, 2022 | 15 | 2022 |
| Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii B Bai, BM Eales, W Huang, KR Ledesma, PR Merlau, G Li, Z Yu, VH Tam Virulence 13 (1), 1920-1927, 2022 | 11 | 2022 |
| Simultaneous in vitro simulation of multiple antimicrobial agents with different elimination half-lives in a pre-clinical infection model I Kesisoglou, BM Eales, KR Ledesma, PR Merlau, VH Tam, W Wang, ... Computers & chemical engineering 155, 107540, 2021 | 6 | 2021 |
| Case commentary: novel therapy for multidrug-resistant Acinetobacter baumannii infection BM Eales, VH Tam Antimicrobial Agents and Chemotherapy 66 (1), e01996-21, 2022 | 5 | 2022 |
| Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach I Kesisoglou, BM Eales, PR Merlau, VH Tam, M Nikolaou Computer methods and programs in biomedicine 227, 107212, 2022 | 3 | 2022 |
| Growth of Acinetobacter baumannii impacted by iron chelation BM Eales, B Bai, PR Merlau, VH Tam Letters in Applied Microbiology 76 (2), ovad019, 2023 | 2 | 2023 |
| Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model BM Eales, CS Hudson, I Kesisoglou, W Wang, M Nikolaou, VH Tam Antibiotics 10 (10), 1256, 2021 | 2 | 2021 |
| MIC Profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates A Zidaru, BM Eales, W Wang, PR Merlau, TM Lasco, AK Sofjan, VH Tam Journal of global antimicrobial resistance 23, 385-387, 2020 | 2 | 2020 |
| Alternative iron-depleted media for cefiderocol susceptibility testing. BM Eales, JE Smith, N Pouya, NS Teran, WR Miller, VH Tam International Journal of Antimicrobial Agents, 107193-107193, 2024 | 1 | 2024 |
| Zileuton ameliorates aminoglycoside and polymyxin-associated acute kidney injury in an animal model CS Hudson, JE Smith, BM Eales, S Kajiji, X Liu, LD Truong, VH Tam Journal of Antimicrobial Chemotherapy 78 (10), 2435-2441, 2023 | 1 | 2023 |
| 500. Impact of an iron chelator on in vitro and in vivo growth of A. baumannii B Eales, B Bai, V Tam Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 557, 2022 | 1 | 2022 |
| Rapid design of combination antimicrobial therapy against Acinetobacter baumannii BM Eales, J Smith, N Pouya, CS Hudson, VH Tam, M Nikolaou Computers & Chemical Engineering 192, 108884, 2025 | | 2025 |
| Population Pharmacokinetics (PopPK) Support for Pediatric Dosing of Biological Products B Eales, NA Helal, O Vattelana, MM Kronfol, EP Fletcher, YM Wang, ... The Journal of Clinical Pharmacology, 2024 | | 2024 |
| Novel Therapy for Acinetobacter baumannii Infections BM Eales | | 2024 |
| 2542. Attenuation of Polymyxin and Aminoglycoside-Associated Nephrotoxicity C Hudson, JE Smith, B Eales, X Liu, S Kajiji, L Truong, V Tam Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2159, 2023 | | 2023 |
| 2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii B Eales, J Smith, C Hudson, N Pouya, V Tam Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 2378, 2023 | | 2023 |
| In vitro model to simulate multiple drugs with distinct elimination half-lives CS Hudson, JE Smith, BM Eales, M Nikolaou, VH Tam International Journal of Antimicrobial Agents 62 (4), 106924, 2023 | | 2023 |
| 1313. MIC Profiling of Ceftazidime-Avibactam (CAZ/AVI) Against Two Carbapenemase producing Klebsiella pneumoniae Isolates A Zidaru, BM Eales, W Wang, P Merlau, T Lasco, AK Sofjan Open Forum Infectious Diseases 7 (Suppl 1), S668, 2020 | | 2020 |
| Deciphering Longitudinal Optical-Density Measurements to Guide the Design of Antibiotic Dosing Regimens: A Model-Based Approach I Kesisoglou, BM Eales, P Merlau, VH Tam, M Nikolaou Available at SSRN 4047864, 0 | | |
